1
|
Poos JM, Grandpierre LDM, van der Ende EL, Panman JL, Papma JM, Seelaar H, van den Berg E, van 't Klooster R, Bron E, Steketee R, Vernooij MW, Pijnenburg YAL, Rombouts SARB, van Swieten J, Jiskoot LC. Longitudinal Brain Atrophy Rates in Presymptomatic Carriers of Genetic Frontotemporal Dementia. Neurology 2022; 99:e2661-e2671. [PMID: 36288997 PMCID: PMC9757869 DOI: 10.1212/wnl.0000000000201292] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Accepted: 08/10/2022] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND AND OBJECTIVES It is important to identify at what age brain atrophy rates in genetic frontotemporal dementia (FTD) start to accelerate and deviate from normal aging effects to find the optimal starting point for treatment. We investigated longitudinal brain atrophy rates in the presymptomatic stage of genetic FTD using normative brain volumetry software. METHODS Presymptomatic GRN, MAPT, and C9orf72 pathogenic variant carriers underwent longitudinal volumetric T1-weighted magnetic resonance imaging of the brain as part of a prospective cohort study. Images were automatically analyzed with Quantib® ND, which consisted of volume measurements (CSF and sum of gray and white matter) of lobes, cerebellum, and hippocampus. All volumes were compared with reference centile curves based on a large population-derived sample of nondemented individuals (n = 4,951). Mixed-effects models were fitted to analyze atrophy rates of the different gene groups as a function of age. RESULTS Thirty-four GRN, 8 MAPT, and 14 C9orf72 pathogenic variant carriers were included (mean age = 52.1, standard deviation = 7.2; 66% female). The mean follow-up duration of the study was 64 ± 33 months (median = 52; range 13-108). GRN pathogenic variant carriers showed a faster decline than the reference centile curves for all brain areas, though relative volumes remained between the 5th and 75th percentiles between the ages of 45 and 70 years. In MAPT pathogenic variant carriers, frontal lobe volume was already at the 5th percentile at age 45 years and showed a further decline between the ages 50 and 60 years. Temporal lobe volume started in the 50th percentile at age 45 years but showed fastest decline over time compared with other brain structures. Frontal, temporal, parietal, and cerebellar volume already started below the 5th percentile compared with the reference centile curves at age 45 years for C9orf72 pathogenic variant carriers, but there was minimal decline over time until the age of 60 years. DISCUSSION We provide evidence for longitudinal brain atrophy in the presymptomatic stage of genetic FTD. The affected brain areas and the age after which atrophy rates start to accelerate and diverge from normal aging slopes differed between gene groups. These results highlight the value of normative volumetry software for disease tracking and staging biomarkers in genetic FTD. These techniques could help in identifying the optimal time window for starting treatment and monitoring treatment response.
Collapse
Affiliation(s)
- Jackie M Poos
- From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom
| | - Leonie D M Grandpierre
- From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom
| | - Emma L van der Ende
- From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom
| | - Jessica L Panman
- From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom
| | - Janne M Papma
- From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom
| | - Harro Seelaar
- From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom
| | - Esther van den Berg
- From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom
| | - Ronald van 't Klooster
- From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom
| | - Esther Bron
- From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom
| | - Rebecca Steketee
- From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom
| | - Meike W Vernooij
- From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom
| | - Yolande A L Pijnenburg
- From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom
| | - Serge A R B Rombouts
- From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom
| | - John van Swieten
- From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom
| | - Lize C Jiskoot
- From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.
| |
Collapse
|
2
|
van der Ende EL, Heller C, Sogorb-Esteve A, Swift IJ, McFall D, Peakman G, Bouzigues A, Poos JM, Jiskoot LC, Panman JL, Papma JM, Meeter LH, Dopper EGP, Bocchetta M, Todd E, Cash D, Graff C, Synofzik M, Moreno F, Finger E, Sanchez-Valle R, Vandenberghe R, Laforce R, Masellis M, Tartaglia MC, Rowe JB, Butler C, Ducharme S, Gerhard A, Danek A, Levin J, Pijnenburg YAL, Otto M, Borroni B, Tagliavini F, de Mendonça A, Santana I, Galimberti D, Sorbi S, Zetterberg H, Huang E, van Swieten JC, Rohrer JD, Seelaar H. Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study. J Neuroinflammation 2022; 19:217. [PMID: 36064709 PMCID: PMC9446850 DOI: 10.1186/s12974-022-02573-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2022] [Accepted: 08/19/2022] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Neuroinflammation is emerging as an important pathological process in frontotemporal dementia (FTD), but biomarkers are lacking. We aimed to determine the value of complement proteins, which are key components of innate immunity, as biomarkers in cerebrospinal fluid (CSF) and plasma of presymptomatic and symptomatic genetic FTD mutation carriers. METHODS We measured the complement proteins C1q and C3b in CSF by ELISAs in 224 presymptomatic and symptomatic GRN, C9orf72 or MAPT mutation carriers and non-carriers participating in the Genetic Frontotemporal Dementia Initiative (GENFI), a multicentre cohort study. Next, we used multiplex immunoassays to measure a panel of 14 complement proteins in plasma of 431 GENFI participants. We correlated complement protein levels with corresponding clinical and neuroimaging data, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP). RESULTS CSF C1q and C3b, as well as plasma C2 and C3, were elevated in symptomatic mutation carriers compared to presymptomatic carriers and non-carriers. In genetic subgroup analyses, these differences remained statistically significant for C9orf72 mutation carriers. In presymptomatic carriers, several complement proteins correlated negatively with grey matter volume of FTD-related regions and positively with NfL and GFAP. In symptomatic carriers, correlations were additionally observed with disease duration and with Mini Mental State Examination and Clinical Dementia Rating scale® plus NACC Frontotemporal lobar degeneration sum of boxes scores. CONCLUSIONS Elevated levels of CSF C1q and C3b, as well as plasma C2 and C3, demonstrate the presence of complement activation in the symptomatic stage of genetic FTD. Intriguingly, correlations with several disease measures in presymptomatic carriers suggest that complement protein levels might increase before symptom onset. Although the overlap between groups precludes their use as diagnostic markers, further research is needed to determine their potential to monitor dysregulation of the complement system in FTD.
Collapse
Affiliation(s)
- Emma L van der Ende
- Alzheimer Center Rotterdam and Department of Neurology, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
| | - Carolin Heller
- UK Dementia Research Institute at University College London, UCL Queen Square Institute of Neurology, London, UK.,Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - Aitana Sogorb-Esteve
- UK Dementia Research Institute at University College London, UCL Queen Square Institute of Neurology, London, UK.,Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - Imogen J Swift
- UK Dementia Research Institute at University College London, UCL Queen Square Institute of Neurology, London, UK.,Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - David McFall
- Department of Pathology, University of California San Francisco, San Francisco, USA
| | - Georgia Peakman
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - Arabella Bouzigues
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - Jackie M Poos
- Alzheimer Center Rotterdam and Department of Neurology, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
| | - Lize C Jiskoot
- Alzheimer Center Rotterdam and Department of Neurology, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
| | - Jessica L Panman
- Alzheimer Center Rotterdam and Department of Neurology, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
| | - Janne M Papma
- Alzheimer Center Rotterdam and Department of Neurology, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
| | - Lieke H Meeter
- Alzheimer Center Rotterdam and Department of Neurology, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
| | - Elise G P Dopper
- Alzheimer Center Rotterdam and Department of Neurology, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
| | - Martina Bocchetta
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - Emily Todd
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - David Cash
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - Caroline Graff
- Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solna, Sweden.,Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Solna, Sweden
| | - Matthis Synofzik
- German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.,Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany
| | - Fermin Moreno
- Cognitive Disorders Unit, Department of Neurology, Hospital Universitario Donostia, San Sebastian, Gipuzkoa, Spain.,Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain
| | - Elizabeth Finger
- Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada
| | - Raquel Sanchez-Valle
- Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Rik Vandenberghe
- Laboratory for Cognitive Neurology, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Louvain, Belgium
| | - Robert Laforce
- Clinique Interdisciplinaire de Mémoire, Département Des Sciences Neurologiques, CHU de Québec, Université Laval, Québec, Canada
| | | | - Maria Carmela Tartaglia
- Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, ON, Canada
| | - James B Rowe
- Cambridge University Centre for Frontotemporal Dementia, University of Cambridge, Cambridge, UK
| | - Chris Butler
- Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK
| | - Simon Ducharme
- McConnell Brain Imaging Centre, Montreal Neurological Institute and McGill University Health Centre, McGill University, Montreal, Québec, Canada
| | - Alexander Gerhard
- Department of Nuclear Medicine and Geriatric Medicine, University Hospital Essen, Essen, Germany.,Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK
| | - Adrian Danek
- Neurologische Klinik Und Poliklinik, Ludwig-Maximilians-Universität München, Munich, Germany
| | - Johannes Levin
- Neurologische Klinik Und Poliklinik, Ludwig-Maximilians-Universität München, Munich, Germany.,German Center for Neurodegenerative Diseases, Munich, Germany.,Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| | - Yolande A L Pijnenburg
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
| | - Markus Otto
- Department of Neurology, Universität Ulm, Ulm, Germany
| | - Barbara Borroni
- Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | | | | | - Isabel Santana
- Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
| | - Daniela Galimberti
- Fondazione IRCCS, Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy.,University of Milan, Centro Dino Ferrari, Milan, Italy
| | - Sandro Sorbi
- Department of Neurofarba, University of Florence, Florence, Italy
| | - Henrik Zetterberg
- UK Dementia Research Institute at University College London, UCL Queen Square Institute of Neurology, London, UK.,Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
| | - Eric Huang
- Department of Pathology, University of California San Francisco, San Francisco, USA
| | - John C van Swieten
- Alzheimer Center Rotterdam and Department of Neurology, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
| | - Jonathan D Rohrer
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - Harro Seelaar
- Alzheimer Center Rotterdam and Department of Neurology, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
| | | |
Collapse
|
3
|
van der Ende EL, Bron EE, Poos JM, Jiskoot LC, Panman JL, Papma JM, Meeter LH, Dopper EGP, Wilke C, Synofzik M, Heller C, Swift IJ, Sogorb-Esteve A, Bouzigues A, Borroni B, Sanchez-Valle R, Moreno F, Graff C, Laforce R, Galimberti D, Masellis M, Tartaglia MC, Finger E, Vandenberghe R, Rowe JB, de Mendonça A, Tagliavini F, Santana I, Ducharme S, Butler CR, Gerhard A, Levin J, Danek A, Otto M, Pijnenburg YAL, Sorbi S, Zetterberg H, Niessen WJ, Rohrer JD, Klein S, van Swieten JC, Venkatraghavan V, Seelaar H. A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain 2022; 145:1805-1817. [PMID: 34633446 PMCID: PMC9166533 DOI: 10.1093/brain/awab382] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Revised: 08/22/2021] [Accepted: 09/09/2021] [Indexed: 11/17/2022] Open
Abstract
Several CSF and blood biomarkers for genetic frontotemporal dementia have been proposed, including those reflecting neuroaxonal loss (neurofilament light chain and phosphorylated neurofilament heavy chain), synapse dysfunction [neuronal pentraxin 2 (NPTX2)], astrogliosis (glial fibrillary acidic protein) and complement activation (C1q, C3b). Determining the sequence in which biomarkers become abnormal over the course of disease could facilitate disease staging and help identify mutation carriers with prodromal or early-stage frontotemporal dementia, which is especially important as pharmaceutical trials emerge. We aimed to model the sequence of biomarker abnormalities in presymptomatic and symptomatic genetic frontotemporal dementia using cross-sectional data from the Genetic Frontotemporal dementia Initiative (GENFI), a longitudinal cohort study. Two-hundred and seventy-five presymptomatic and 127 symptomatic carriers of mutations in GRN, C9orf72 or MAPT, as well as 247 non-carriers, were selected from the GENFI cohort based on availability of one or more of the aforementioned biomarkers. Nine presymptomatic carriers developed symptoms within 18 months of sample collection ('converters'). Sequences of biomarker abnormalities were modelled for the entire group using discriminative event-based modelling (DEBM) and for each genetic subgroup using co-initialized DEBM. These models estimate probabilistic biomarker abnormalities in a data-driven way and do not rely on previous diagnostic information or biomarker cut-off points. Using cross-validation, subjects were subsequently assigned a disease stage based on their position along the disease progression timeline. CSF NPTX2 was the first biomarker to become abnormal, followed by blood and CSF neurofilament light chain, blood phosphorylated neurofilament heavy chain, blood glial fibrillary acidic protein and finally CSF C3b and C1q. Biomarker orderings did not differ significantly between genetic subgroups, but more uncertainty was noted in the C9orf72 and MAPT groups than for GRN. Estimated disease stages could distinguish symptomatic from presymptomatic carriers and non-carriers with areas under the curve of 0.84 (95% confidence interval 0.80-0.89) and 0.90 (0.86-0.94) respectively. The areas under the curve to distinguish converters from non-converting presymptomatic carriers was 0.85 (0.75-0.95). Our data-driven model of genetic frontotemporal dementia revealed that NPTX2 and neurofilament light chain are the earliest to change among the selected biomarkers. Further research should investigate their utility as candidate selection tools for pharmaceutical trials. The model's ability to accurately estimate individual disease stages could improve patient stratification and track the efficacy of therapeutic interventions.
Collapse
Affiliation(s)
- Emma L van der Ende
- Department of Neurology and Alzheimer Center, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Esther E Bron
- Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Jackie M Poos
- Department of Neurology and Alzheimer Center, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Lize C Jiskoot
- Department of Neurology and Alzheimer Center, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Jessica L Panman
- Department of Neurology and Alzheimer Center, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Janne M Papma
- Department of Neurology and Alzheimer Center, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Lieke H Meeter
- Department of Neurology and Alzheimer Center, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Elise G P Dopper
- Department of Neurology and Alzheimer Center, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Carlo Wilke
- German Center for Neurodegenerative Diseases (DZNE), 72076 Tübingen, Germany
- Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, 72076 Tübingen, Germany
| | - Matthis Synofzik
- German Center for Neurodegenerative Diseases (DZNE), 72076 Tübingen, Germany
- Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, 72076 Tübingen, Germany
| | - Carolin Heller
- UK Dementia Research Institute at University College London, UCL Institute of Neurology, Queen Square, WC1N 3BG London, UK
| | - Imogen J Swift
- UK Dementia Research Institute at University College London, UCL Institute of Neurology, Queen Square, WC1N 3BG London, UK
| | - Aitana Sogorb-Esteve
- UK Dementia Research Institute at University College London, UCL Institute of Neurology, Queen Square, WC1N 3BG London, UK
- Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, WC1N 3BG London, UK
| | - Arabella Bouzigues
- Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, WC1N 3BG London, UK
| | - Barbara Borroni
- Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, 25121 Brescia, Italy
| | - Raquel Sanchez-Valle
- Alzheimer’s Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, IDIBAPS, University of Barcelona, 08036 Barcelona, Spain
| | - Fermin Moreno
- Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, 20014 Gipuzkoa, Spain
- Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain
| | - Caroline Graff
- Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, 17176 Solna, Sweden
- Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, 17176 Solna, Sweden
| | - Robert Laforce
- Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, Université Laval, G1Z 1J4 Québec, Canada
| | - Daniela Galimberti
- Centro Dino Ferrari, University of Milan, 20122 Milan, Italy
- Neurodegenerative Diseases Unit, Fondazione IRCCS, Ospedale Maggiore Policlinico, 20122 Milan, Italy
| | - Mario Masellis
- Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, ON M4N 3M5 Toronto, Canada
| | - Maria Carmela Tartaglia
- Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, M5S 1A8 Toronto, Canada
| | - Elizabeth Finger
- Department of Clinical Neurological Sciences, University of Western Ontario, ON N6A 3K7 London, Ontario, Canada
| | - Rik Vandenberghe
- Laboratory for Cognitive Neurology, Department of Neurosciences, Leuven Brain Institute, KU Leuven, 3000 Leuven, Belgium
| | - James B Rowe
- Cambridge University Centre for Frontotemporal Dementia, University of Cambridge, CB2 0SZ Cambridge, UK
| | | | | | - Isabel Santana
- Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal
| | - Simon Ducharme
- McConnell Brain Imaging Centre, Montreal Neurological Institute and McGill University Health Centre, McGill University, 3801 Montreal, Québec, Canada
| | - Christopher R Butler
- Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, OX3 9DU Oxford, UK
- Department of Brain Sciences, Imperial College London, SW7 2AZ London, UK
| | - Alexander Gerhard
- Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, M20 3LJ Manchester, UK
- Department of Nuclear Medicine and Geriatric Medicine, University Hospital Essen, 45 147 Essen, Germany
| | - Johannes Levin
- Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, 81377 Munich, Germany
- German Center for Neurodegenerative Diseases, 81377 Munich, Germany
- Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany
| | - Adrian Danek
- Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, 81377 Munich, Germany
| | - Markus Otto
- Department of Neurology, University of Ulm, 89081 Ulm, Germany
| | - Yolande A L Pijnenburg
- Department of Neurology, Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center, 1105 AZ Amsterdam, The Netherlands
| | - Sandro Sorbi
- Department of Neurofarba, University of Florence, 50139 Florence, Italy
| | - Henrik Zetterberg
- UK Dementia Research Institute at University College London, UCL Institute of Neurology, Queen Square, WC1N 3BG London, UK
- Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, 405 30 Mölndal, Sweden
| | - Wiro J Niessen
- Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Jonathan D Rohrer
- Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, WC1N 3BG London, UK
| | - Stefan Klein
- Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - John C van Swieten
- Department of Neurology and Alzheimer Center, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Vikram Venkatraghavan
- Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Harro Seelaar
- Department of Neurology and Alzheimer Center, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
| |
Collapse
|
4
|
van der Ende E, Bron EE, Poos JM, Jiskoot LC, Panman JL, Papma JM, Wilke C, Synofzik M, Heller C, Swift IJ, Esteve AS, Bouzigues A, Borroni B, Sanchez‐Valle R, Moreno F, Graff C, Laforce R, Galimberti D, Masellis M, Tartaglia MC, Finger E, Vandenberghe R, Rowe JB, Mendonca A, Tagliavini F, Santana I, Ducharme S, Butler C, Gerhard A, Levin J, Danek A, Otto M, Pijnenburg YA, Frisoni GB, Sorbi S, Ghidoni R, Niessen WJ, Rohrer JD, Klein S, van Swieten JC, Venkatraghavan V, Seelaar H. A data‐driven disease progression model of fluid biomarkers in genetic FTD. Alzheimers Dement 2021. [DOI: 10.1002/alz.053497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
| | - Esther E. Bron
- Biomedical Imaging Group Rotterdam, Departments of Medical Informatics and Radiology & Nuclear Medicine, Erasmus MC Rotterdam Netherlands
| | | | | | | | - Janne M. Papma
- Department of Neurology, Erasmus University Medical Center Rotterdam Netherlands
| | - Carlo Wilke
- German Center for Neurodegenerative Diseases (DZNE), University of Tubingen Tubingen Germany
- Center for Neurology & Hertie Institute for Clinical Brain Research Tubingen Germany
| | - Matthis Synofzik
- German Center for Neurodegenerative Diseases (DZNE), University of Tubingen Tubingen Germany
- Centre for Neurology and Hertie‐Institute for Clinical Brain Research Hoppe‐Seyler‐Str Tuebingen Germany
| | - Carolin Heller
- UK Dementia Research Institute at UCL, London United Kingdom
| | - Imogen J. Swift
- UK Dementia Research Institute at UCL, London United Kingdom
| | - Aitana Sogorb Esteve
- UK Dementia Research Institute at UCL, London United Kingdom
- Dementia Research Centre at UCL Queen Square Institute of Neurology, London United Kingdom
| | - Arabella Bouzigues
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London London United Kingdom
| | - Barbara Borroni
- Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia Brescia Italy
| | - Raquel Sanchez‐Valle
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
| | - Fermin Moreno
- Hospital Universitario Donostia, San Sebastian Spain
| | - Caroline Graff
- Karolinska Institutet, Department NVS, Division of Neurogeriatrics, Karolinska Institutet Stockholm Sweden
- Unit for Hereditary Dementia, Theme Aging, Karolinska University Hospital‐Solna Stockholm Sweden
| | - Robert Laforce
- Clinique Interdisciplinaire de Mémoire, CHU de Québec/Université Laval/Hôpital de l’Enfant‐Jésus Quebec City QC Canada
| | - Daniela Galimberti
- University of Milan Milan Italy
- Department of Biomedical, Surgical and Dental Sciences, University of Milan Milan Italy
| | - Mario Masellis
- Cognitive and Movement Disorders Clinic, Sunnybrook Health Sciences Center Toronto ON Canada
| | - Maria Carmela Tartaglia
- Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto Toronto ON Canada
| | - Elizabeth Finger
- Department of Clinical Neurological Sciences, University of Western Ontario London ON Canada
| | - Rik Vandenberghe
- Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven Leuven Belgium
| | - James B. Rowe
- Cambridge University Centre for Frontotemporal Dementia, University of Cambridge Cambridge United Kingdom
| | | | - Fabrizio Tagliavini
- Division of Neurology V/Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy
| | - Isabel Santana
- Center for Neurosciences and Cell Biology, University of Coimbra Coimbra Portugal
| | - Simon Ducharme
- Montreal Neurological Institute, McGill University Montreal QC Canada
| | | | - Alexander Gerhard
- Divison of Neuroscience and Experimental Psychology, University of Manchester Manchester United Kingdom
- Nuclear Medicine and Geriatric Medicine, University Hospital Essen Essen Germany
| | - Johannes Levin
- LMU Munich Germany
- German Center for Neurodegenerative Diseases (DZNE) Munich Germany
- Munich Cluster for Systems Neurology (SyNergy) Munich Germany
| | | | | | - Yolande A.L. Pijnenburg
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC Amsterdam Netherlands
| | | | | | - Roberta Ghidoni
- IRCCS Centro San Giovanni di Dio Fatebenefratelli Brescia Italy
| | - Wiro J. Niessen
- Radiology & Nuclear Medicine, Erasmus MC Rotterdam Rotterdam Netherlands
| | - Jonathan D. Rohrer
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London London United Kingdom
| | - Stefan Klein
- Radiology and Nuclear Medicine, Erasmus MC Rotterdam Netherlands
| | - John C van Swieten
- Alzheimer Center and Department of Neurology, Erasmus University Medical Center Rotterdam Netherlands
| | | | | |
Collapse
|
5
|
Panman JL, Venkatraghavan V, van der Ende EL, Steketee RME, Jiskoot LC, Poos JM, Dopper EGP, Meeter LHH, Donker Kaat L, Rombouts SARB, Vernooij MW, Kievit AJA, Premi E, Cosseddu M, Bonomi E, Olives J, Rohrer JD, Sánchez-Valle R, Borroni B, Bron EE, Van Swieten JC, Papma JM, Klein S. Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia. J Neurol Neurosurg Psychiatry 2021; 92:494-501. [PMID: 33452053 PMCID: PMC8053353 DOI: 10.1136/jnnp-2020-323541] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Revised: 10/19/2020] [Accepted: 11/24/2020] [Indexed: 12/13/2022]
Abstract
OBJECTIVE Progranulin-related frontotemporal dementia (FTD-GRN) is a fast progressive disease. Modelling the cascade of multimodal biomarker changes aids in understanding the aetiology of this disease and enables monitoring of individual mutation carriers. In this cross-sectional study, we estimated the temporal cascade of biomarker changes for FTD-GRN, in a data-driven way. METHODS We included 56 presymptomatic and 35 symptomatic GRN mutation carriers, and 35 healthy non-carriers. Selected biomarkers were neurofilament light chain (NfL), grey matter volume, white matter microstructure and cognitive domains. We used discriminative event-based modelling to infer the cascade of biomarker changes in FTD-GRN and estimated individual disease severity through cross-validation. We derived the biomarker cascades in non-fluent variant primary progressive aphasia (nfvPPA) and behavioural variant FTD (bvFTD) to understand the differences between these phenotypes. RESULTS Language functioning and NfL were the earliest abnormal biomarkers in FTD-GRN. White matter tracts were affected before grey matter volume, and the left hemisphere degenerated before the right. Based on individual disease severities, presymptomatic carriers could be delineated from symptomatic carriers with a sensitivity of 100% and specificity of 96.1%. The estimated disease severity strongly correlated with functional severity in nfvPPA, but not in bvFTD. In addition, the biomarker cascade in bvFTD showed more uncertainty than nfvPPA. CONCLUSION Degeneration of axons and language deficits are indicated to be the earliest biomarkers in FTD-GRN, with bvFTD being more heterogeneous in disease progression than nfvPPA. Our data-driven model could help identify presymptomatic GRN mutation carriers at risk of conversion to the clinical stage.
Collapse
Affiliation(s)
- Jessica L Panman
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands .,Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
| | - Vikram Venkatraghavan
- Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
| | | | - Rebecca M E Steketee
- Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Lize C Jiskoot
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Jackie M Poos
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Elise G P Dopper
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Lieke H H Meeter
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Laura Donker Kaat
- Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Serge A R B Rombouts
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.,Institute for Psychology, Leiden University, Leiden, The Netherlands
| | - Meike W Vernooij
- Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Anneke J A Kievit
- Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Enrico Premi
- Centre for Neurodegenerative Disorders, University of Brescia, Brescia, Italy
| | - Maura Cosseddu
- Centre for Neurodegenerative Disorders, University of Brescia, Brescia, Italy
| | - Elisa Bonomi
- Centre for Neurodegenerative Disorders, University of Brescia, Brescia, Italy
| | - Jaume Olives
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic de Barcelona, Barcelona, Spain
| | | | - Raquel Sánchez-Valle
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | - Barbara Borroni
- Centre for Neurodegenerative Disorders, University of Brescia, Brescia, Italy
| | - Esther E Bron
- Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
| | - John C Van Swieten
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Janne M Papma
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Stefan Klein
- Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
| | | |
Collapse
|
6
|
Feis RA, van der Grond J, Bouts MJRJ, Panman JL, Poos JM, Schouten TM, de Vos F, Jiskoot LC, Dopper EGP, van Buchem MA, van Swieten JC, Rombouts SARB. Classification using fractional anisotropy predicts conversion in genetic frontotemporal dementia, a proof of concept. Brain Commun 2021; 2:fcaa079. [PMID: 33543126 PMCID: PMC7846185 DOI: 10.1093/braincomms/fcaa079] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2019] [Revised: 04/29/2020] [Accepted: 05/11/2020] [Indexed: 11/14/2022] Open
Abstract
Frontotemporal dementia is a highly heritable and devastating neurodegenerative disease. About 10–20% of all frontotemporal dementia is caused by known pathogenic mutations, but a reliable tool to predict clinical conversion in mutation carriers is lacking. In this retrospective proof-of-concept case-control study, we investigate whether MRI-based and cognition-based classifiers can predict which mutation carriers from genetic frontotemporal dementia families will develop symptoms (‘convert’) within 4 years. From genetic frontotemporal dementia families, we included 42 presymptomatic frontotemporal dementia mutation carriers. We acquired anatomical, diffusion-weighted imaging, and resting-state functional MRI, as well as neuropsychological data. After 4 years, seven mutation carriers had converted to frontotemporal dementia (‘converters’), while 35 had not (‘non-converters’). We trained regularized logistic regression models on baseline MRI and cognitive data to predict conversion to frontotemporal dementia within 4 years, and quantified prediction performance using area under the receiver operating characteristic curves. The prediction model based on fractional anisotropy, with highest contribution of the forceps minor, predicted conversion to frontotemporal dementia beyond chance level (0.81 area under the curve, family-wise error corrected P = 0.025 versus chance level). Other MRI-based and cognitive features did not outperform chance level. Even in a small sample, fractional anisotropy predicted conversion in presymptomatic frontotemporal dementia mutation carriers beyond chance level. After validation in larger data sets, conversion prediction in genetic frontotemporal dementia may facilitate early recruitment into clinical trials.
Collapse
Affiliation(s)
- Rogier A Feis
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, 2333 ZA, Leiden, the Netherlands.,Institute of Psychology, Leiden University, 2333 AK, Leiden, the Netherlands
| | - Jeroen van der Grond
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands
| | - Mark J R J Bouts
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, 2333 ZA, Leiden, the Netherlands.,Institute of Psychology, Leiden University, 2333 AK, Leiden, the Netherlands
| | - Jessica L Panman
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Department of Neurology, Erasmus Medical Centre, 3015 GD, Rotterdam, the Netherlands
| | - Jackie M Poos
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Department of Neurology, Erasmus Medical Centre, 3015 GD, Rotterdam, the Netherlands
| | - Tijn M Schouten
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, 2333 ZA, Leiden, the Netherlands.,Institute of Psychology, Leiden University, 2333 AK, Leiden, the Netherlands
| | - Frank de Vos
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, 2333 ZA, Leiden, the Netherlands.,Institute of Psychology, Leiden University, 2333 AK, Leiden, the Netherlands
| | - Lize C Jiskoot
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Department of Neurology, Erasmus Medical Centre, 3015 GD, Rotterdam, the Netherlands.,Dementia Research Centre, University College London, London, WC1N 3AR, UK
| | - Elise G P Dopper
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Department of Neurology, Erasmus Medical Centre, 3015 GD, Rotterdam, the Netherlands
| | - Mark A van Buchem
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, 2333 ZA, Leiden, the Netherlands
| | - John C van Swieten
- Department of Neurology, Erasmus Medical Centre, 3015 GD, Rotterdam, the Netherlands
| | - Serge A R B Rombouts
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, 2333 ZA, Leiden, the Netherlands.,Institute of Psychology, Leiden University, 2333 AK, Leiden, the Netherlands
| |
Collapse
|
7
|
Venkatraghavan V, Panman JL, van der Ende EL, Steketee R, Jiskoot LC, Poos JM, Dopper EG, Meeter LH, Kaat LD, Rombouts SA, Vernooij MW, Kievit AJ, Premi E, Cosseddu M, Bonomi E, Olives J, Rohrer JD, Sanchez‐Valle R, Borroni B, Bron EE, van Swieten JC, Papma JM, Klein S. Modelling the cascade of biomarker changes in progranulin‐related frontotemporal dementia. Alzheimers Dement 2020. [DOI: 10.1002/alz.040934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
| | - Jessica L. Panman
- Erasmus MC Rotterdam Netherlands
- Leiden University Medical Center Leiden Netherlands
| | | | | | - Lize C. Jiskoot
- Erasmus MC Rotterdam Netherlands
- Dementia Research Centre Queen Square Institute of Neurology University College London London United Kingdom
| | - Jackie M. Poos
- Leiden University Medical Center Leiden Netherlands
- Erasmus Medical Centre Rotterdam Netherlands
| | | | | | | | - Serge A.R.B. Rombouts
- Leiden University Medical Center Leiden Netherlands
- Leiden University Leiden Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | - Janne M. Papma
- Erasmus MC ‐ University Medical Center Rotterdam Netherlands
| | | | | |
Collapse
|
8
|
van der Ende EL, Xiao M, Xu D, Poos JM, Panman JL, Jiskoot LC, Meeter LH, Dopper EG, Papma JM, Heller C, Convery R, Moore K, Bocchetta M, Neason M, Peakman G, Cash DM, Teunissen CE, Graff C, Synofzik M, Moreno F, Finger E, Sánchez-Valle R, Vandenberghe R, Laforce R, Masellis M, Tartaglia MC, Rowe JB, Butler CR, Ducharme S, Gerhard A, Danek A, Levin J, Pijnenburg YA, Otto M, Borroni B, Tagliavini F, de Mendonca A, Santana I, Galimberti D, Seelaar H, Rohrer JD, Worley PF, van Swieten JC. Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. J Neurol Neurosurg Psychiatry 2020; 91:612-621. [PMID: 32273328 PMCID: PMC7279197 DOI: 10.1136/jnnp-2019-322493] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2019] [Revised: 02/26/2020] [Accepted: 03/02/2020] [Indexed: 12/11/2022]
Abstract
INTRODUCTION Synapse dysfunction is emerging as an early pathological event in frontotemporal dementia (FTD), however biomarkers are lacking. We aimed to investigate the value of cerebrospinal fluid (CSF) neuronal pentraxins (NPTXs), a family of proteins involved in homeostatic synapse plasticity, as novel biomarkers in genetic FTD. METHODS We included 106 presymptomatic and 54 symptomatic carriers of a pathogenic mutation in GRN, C9orf72 or MAPT, and 70 healthy non-carriers participating in the Genetic Frontotemporal dementia Initiative (GENFI), all of whom had at least one CSF sample. We measured CSF concentrations of NPTX2 using an in-house ELISA, and NPTX1 and NPTX receptor (NPTXR) by Western blot. We correlated NPTX2 with corresponding clinical and neuroimaging datasets as well as with CSF neurofilament light chain (NfL) using linear regression analyses. RESULTS Symptomatic mutation carriers had lower NPTX2 concentrations (median 643 pg/mL, IQR (301-872)) than presymptomatic carriers (1003 pg/mL (624-1358), p<0.001) and non-carriers (990 pg/mL (597-1373), p<0.001) (corrected for age). Similar results were found for NPTX1 and NPTXR. Among mutation carriers, NPTX2 concentration correlated with several clinical disease severity measures, NfL and grey matter volume of the frontal, temporal and parietal lobes, insula and whole brain. NPTX2 predicted subsequent decline in phonemic verbal fluency and Clinical Dementia Rating scale plus FTD modules. In longitudinal CSF samples, available in 13 subjects, NPTX2 decreased around symptom onset and in the symptomatic stage. DISCUSSION We conclude that NPTX2 is a promising synapse-derived disease progression biomarker in genetic FTD.
Collapse
Affiliation(s)
- Emma L van der Ende
- Department of Neurology and Alzheimer Center, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Meifang Xiao
- Solomon H Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
| | - Desheng Xu
- Solomon H Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
| | - Jackie M Poos
- Department of Neurology and Alzheimer Center, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Jessica L Panman
- Department of Neurology and Alzheimer Center, Erasmus University Medical Center, Rotterdam, Netherlands
- Department of Radiology, Leiden University Medical Center, Leiden, Netherlands
| | - Lize C Jiskoot
- Department of Neurology and Alzheimer Center, Erasmus University Medical Center, Rotterdam, Netherlands
- Dementia Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Lieke H Meeter
- Department of Neurology and Alzheimer Center, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Elise Gp Dopper
- Department of Neurology and Alzheimer Center, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Janne M Papma
- Department of Neurology and Alzheimer Center, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Carolin Heller
- Dementia Research Institute, Department of Neurodegenerative Disease, University College London, London, United Kingdom
| | - Rhian Convery
- Dementia Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Katrina Moore
- Dementia Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Martina Bocchetta
- Dementia Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Mollie Neason
- Dementia Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Georgia Peakman
- Dementia Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - David M Cash
- Dementia Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Charlotte E Teunissen
- Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam University Medical Center, Amsterdam, Netherlands
| | - Caroline Graff
- Karolinska Institutet, Dept NVS, Division of Neurogeriatrics, Bioclinicum, Stockholm, Sweden
- Unit of Hereditary Dementia, Theme Aging, Karolinska University Hospital-Solna, Stockholm, Sweden
| | - Matthis Synofzik
- German Center for Neurodegenerative Diseases (DZNE), University of Tübingen, Tübingen, Germany
- Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, Tübingen, Germany
| | - Fermin Moreno
- Department of Neurology, Donostia University Hospital, San Sebastian, Gipuzkoa, Spain
| | - Elizabeth Finger
- Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada
| | - Raquel Sánchez-Valle
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clinic de Barcelona, Barcelona, Spain
| | - Rik Vandenberghe
- Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium
| | - Robert Laforce
- Clinique Interdisciplinaire de Mémoire du CHU de Québec, Département des Sciences Neurologiques, Université Laval, Québec, Quebec City, Canada
| | - Mario Masellis
- Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
| | - Maria Carmela Tartaglia
- Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Ontario, Canada
| | - James B Rowe
- Cambridge University Centre for Frontotemporal Dementia, University of Cambridge, Cambridge, United Kingdom
| | | | - Simon Ducharme
- Montreal Neurological Institute and McGill University Health Centre, McGill University, Montreal, Québec, Canada
| | - Alex Gerhard
- Department of Nuclear Medicine and Geriatric Medicine, University Hospital Essen, Essen, Germany
- Divison of Neuroscience and Experimental Psychology, University of Manchester, Manchester, United Kingdom
| | - Adrian Danek
- Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Munich, Germany
| | - Johannes Levin
- Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Munich, Germany
- German Center for Neurodegenerative Diseases, (DZNE), Munich, Germany
- Munich Cluster for Systems Neurology, (SyNergy), Munich, Germany
| | - Yolande Al Pijnenburg
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands
| | - Markus Otto
- Department of Neurology, Universität Ulm, Ulm, Germany
| | - Barbara Borroni
- Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | | | | | - Isabel Santana
- Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
| | - Daniela Galimberti
- Department of Neurological Sciences, Dino Ferrari Center, University of Milan, Milan, Italy
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
| | - Harro Seelaar
- Department of Neurology and Alzheimer Center, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Jonathan D Rohrer
- Dementia Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Paul F Worley
- Solomon H Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
| | - John C van Swieten
- Department of Neurology and Alzheimer Center, Erasmus University Medical Center, Rotterdam, Netherlands
| |
Collapse
|
9
|
Poos JM, Jiskoot LC, Leijdesdorff SMJ, Seelaar H, Panman JL, van der Ende EL, Mol MO, Meeter LHH, Pijnenburg YAL, Donker Kaat L, de Jong FJ, van Swieten JC, Papma JM, van den Berg E. Correction to: Cognitive profiles discriminate between genetic variants of behavioral frontotemporal dementia. J Neurol 2020; 267:1613-1614. [PMID: 32219556 PMCID: PMC7293670 DOI: 10.1007/s00415-020-09784-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Affiliation(s)
- J M Poos
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands. .,Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
| | - L C Jiskoot
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands.,Dementia Research Center, University College London, London, UK
| | - S M J Leijdesdorff
- Department of Psychiatry and Psychology, Maastricht University, Maastricht, The Netherlands
| | - H Seelaar
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands
| | - J L Panman
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands.,Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
| | - E L van der Ende
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands
| | - M O Mol
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands
| | - L H H Meeter
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands
| | - Y A L Pijnenburg
- Department of Neurology, Alzheimer Center, Location VU University Medical CenterAmsterdam Neuroscience, Amsterdam University Medical Center, Amsterdam, The Netherlands
| | - L Donker Kaat
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands.,Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands
| | - F J de Jong
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands
| | - J C van Swieten
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands
| | - J M Papma
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands
| | - E van den Berg
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands
| |
Collapse
|
10
|
Poos JM, Jiskoot LC, Leijdesdorff SMJ, Seelaar H, Panman JL, van der Ende EL, Mol MO, Meeter LHH, Pijnenburg YAL, Donker Kaat L, de Jong FJ, van Swieten JC, Papma JM, van den Berg E. Cognitive profiles discriminate between genetic variants of behavioral frontotemporal dementia. J Neurol 2020; 267:1603-1612. [PMID: 32052166 PMCID: PMC7293665 DOI: 10.1007/s00415-020-09738-y] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Revised: 01/28/2020] [Accepted: 01/30/2020] [Indexed: 12/12/2022]
Abstract
Introduction Trials to test disease-modifying treatments for frontotemporal dementia are eagerly awaited and sensitive instruments to assess potential treatment effects are increasingly urgent, yet lacking thus far. We aimed to identify gene-specific instruments assessing clinical onset and disease progression by comparing cognitive functioning between bvFTD patients across genetic mutations. Methods We examined differences in 7 cognitive domains between bvFTD patients with GRN (n = 20), MAPT (n = 29) or C9orf72 (n = 31) mutations, and non-carriers (n = 24), and described longitudinal (M = 22.6 months, SD = 16.6) data in a subsample (n = 27). Results Patients showed overall cognitive impairment, except memory recall, working memory and visuoconstruction. GRN patients performed lower on executive function (mean difference − 2.1; 95%CI − 4.1 to − 0.5) compared to MAPT and lower on attention compared to MAPT (mean difference − 2.5; 95%CI − 4.7 to − 0.3) and C9orf72 (mean difference − 2.4; 95%CI − 4.5 to − 0.3). Only MAPT patients were impaired on delayed recall (mean difference − 1.4; 95%CI − 2.1 to − 0.7). GRN patients declined rapidly on attention and memory, MAPT declined in confrontation naming, whereas C9orf72 patients were globally impaired but remained relatively stable over time on all cognitive domains. Discussion This study shows gene-specific cognitive profiles in bvFTD, which underlines the value of neuropsychological tests as outcome measures in upcoming trials for genetic bvFTD. Electronic supplementary material The online version of this article (10.1007/s00415-020-09738-y) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- J M Poos
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands. .,Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
| | - L C Jiskoot
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands.,Dementia Research Center, University College London, London, UK
| | - S M J Leijdesdorff
- Department of Psychiatry and Psychology, Maastricht University, Maastricht, The Netherlands
| | - H Seelaar
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands
| | - J L Panman
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands.,Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
| | - E L van der Ende
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands
| | - M O Mol
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands
| | - L H H Meeter
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands
| | - Y A L Pijnenburg
- Department of Neurology, Alzheimer Center, Location VU University Medical CenterAmsterdam Neuroscience, Amsterdam University Medical Center, Amsterdam, The Netherlands
| | - L Donker Kaat
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands.,Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands
| | - F J de Jong
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands
| | - J C van Swieten
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands
| | - J M Papma
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands
| | - E van den Berg
- Department of Neurology, Alzheimer Center, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands
| |
Collapse
|
11
|
van der Ende EL, Meeter LH, Poos JM, Panman JL, Jiskoot LC, Dopper EGP, Papma JM, de Jong FJ, Verberk IMW, Teunissen C, Rizopoulos D, Heller C, Convery RS, Moore KM, Bocchetta M, Neason M, Cash DM, Borroni B, Galimberti D, Sanchez-Valle R, Laforce R, Moreno F, Synofzik M, Graff C, Masellis M, Carmela Tartaglia M, Rowe JB, Vandenberghe R, Finger E, Tagliavini F, de Mendonça A, Santana I, Butler C, Ducharme S, Gerhard A, Danek A, Levin J, Otto M, Frisoni GB, Cappa S, Pijnenburg YAL, Rohrer JD, van Swieten JC, Warren JD, Fox NC, Woollacott IO, Shafei R, Greaves C, Guerreiro R, Bras J, Thomas DL, Nicholas J, Mead S, van Minkelen R, Barandiaran M, Indakoetxea B, Gabilondo A, Tainta M, de Arriba M, Gorostidi A, Zulaica M, Villanua J, Diaz Z, Borrego-Ecija S, Olives J, Lladó A, Balasa M, Antonell A, Bargallo N, Premi E, Cosseddu M, Gazzina S, Padovani A, Gasparotti R, Archetti S, Black S, Mitchell S, Rogaeva E, Freedman M, Keren R, Tang-Wai D, Öijerstedt L, Andersson C, Jelic V, Thonberg H, Arighi A, Fenoglio C, Scarpini E, Fumagalli G, Cope T, Timberlake C, Rittman T, Shoesmith C, Bartha R, Rademakers R, Wilke C, Karnath HO, Bender B, Bruffaerts R, Vandamme P, Vandenbulcke M, Ferreira CB, Miltenberger G, Maruta C, Verdelho A, Afonso S, Taipa R, Caroppo P, Di Fede G, Giaccone G, Prioni S, Redaelli V, Rossi G, Tiraboschi P, Duro D, Rosario Almeida M, Castelo-Branco M, João Leitão M, Tabuas-Pereira M, Santiago B, Gauthier S, Schonecker S, Semler E, Anderl-Straub S, Benussi L, Binetti G, Ghidoni R, Pievani M, Lombardi G, Nacmias B, Ferrari C, Bessi V. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol 2019; 18:1103-1111. [PMID: 31701893 DOI: 10.1016/s1474-4422(19)30354-0] [Citation(s) in RCA: 119] [Impact Index Per Article: 23.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2019] [Revised: 07/26/2019] [Accepted: 08/13/2019] [Indexed: 12/15/2022]
Abstract
BACKGROUND Neurofilament light chain (NfL) is a promising blood biomarker in genetic frontotemporal dementia, with elevated concentrations in symptomatic carriers of mutations in GRN, C9orf72, and MAPT. A better understanding of NfL dynamics is essential for upcoming therapeutic trials. We aimed to study longitudinal NfL trajectories in people with presymptomatic and symptomatic genetic frontotemporal dementia. METHODS We recruited participants from 14 centres collaborating in the Genetic Frontotemporal Dementia Initiative (GENFI), which is a multicentre cohort study of families with genetic frontotemporal dementia done across Europe and Canada. Eligible participants (aged ≥18 years) either had frontotemporal dementia due to a pathogenic mutation in GRN, C9orf72, or MAPT (symptomatic mutation carriers) or were healthy at-risk first-degree relatives (either presymptomatic mutation carriers or non-carriers), and had at least two serum samples with a time interval of 6 months or more. Participants were excluded if they had neurological comorbidities that were likely to affect NfL, including cerebrovascular events. We measured NfL longitudinally in serum samples collected between June 8, 2012, and Dec 8, 2017, through follow-up visits annually or every 2 years, which also included MRI and neuropsychological assessments. Using mixed-effects models, we analysed NfL changes over time and correlated them with longitudinal imaging and clinical parameters, controlling for age, sex, and study site. The primary outcome was the course of NfL over time in the various stages of genetic frontotemporal dementia. FINDINGS We included 59 symptomatic carriers and 149 presymptomatic carriers of a mutation in GRN, C9orf72, or MAPT, and 127 non-carriers. Nine presymptomatic carriers became symptomatic during follow-up (so-called converters). Baseline NfL was elevated in symptomatic carriers (median 52 pg/mL [IQR 24-69]) compared with presymptomatic carriers (9 pg/mL [6-13]; p<0·0001) and non-carriers (8 pg/mL [6-11]; p<0·0001), and was higher in converters than in non-converting carriers (19 pg/mL [17-28] vs 8 pg/mL [6-11]; p=0·0007; adjusted for age). During follow-up, NfL increased in converters (b=0·097 [SE 0·018]; p<0·0001). In symptomatic mutation carriers overall, NfL did not change during follow-up (b=0·017 [SE 0·010]; p=0·101) and remained elevated. Rates of NfL change over time were associated with rate of decline in Mini Mental State Examination (b=-94·7 [SE 33·9]; p=0·003) and atrophy rate in several grey matter regions, but not with change in Frontotemporal Lobar Degeneration-Clinical Dementia Rating scale score (b=-3·46 [SE 46·3]; p=0·941). INTERPRETATION Our findings show the value of blood NfL as a disease progression biomarker in genetic frontotemporal dementia and suggest that longitudinal NfL measurements could identify mutation carriers approaching symptom onset and capture rates of brain atrophy. The characterisation of NfL over the course of disease provides valuable information for its use as a treatment effect marker. FUNDING ZonMw and the Bluefield project.
Collapse
Affiliation(s)
- Emma L van der Ende
- Department of Neurology and Alzheimer Center, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands
| | - Lieke H Meeter
- Department of Neurology and Alzheimer Center, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands
| | - Jackie M Poos
- Department of Neurology and Alzheimer Center, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands
| | - Jessica L Panman
- Department of Neurology and Alzheimer Center, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands; Department of Radiology, Leiden University Medical Center, Leiden, Netherlands
| | - Lize C Jiskoot
- Department of Neurology and Alzheimer Center, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands; Dementia Research Institute, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - Elise G P Dopper
- Department of Neurology and Alzheimer Center, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands
| | - Janne M Papma
- Department of Neurology and Alzheimer Center, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands
| | - Frank Jan de Jong
- Department of Neurology and Alzheimer Center, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands
| | - Inge M W Verberk
- Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands
| | - Charlotte Teunissen
- Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands
| | - Dimitris Rizopoulos
- Department of Biostatistics, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands
| | - Carolin Heller
- Dementia Research Institute, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - Rhian S Convery
- Dementia Research Institute, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - Katrina M Moore
- Dementia Research Institute, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - Martina Bocchetta
- Dementia Research Institute, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - Mollie Neason
- Dementia Research Institute, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - David M Cash
- Dementia Research Institute, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - Barbara Borroni
- Centre for Neurodegenerative Disorders, Neurology unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Daniela Galimberti
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy; University of Milan, Centro Dino Ferrari, Milan, Italy
| | - Raquel Sanchez-Valle
- Hospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain
| | | | - Fermin Moreno
- Department of Neurology, Hospital Universitario Donostia, Gipuzkoa, Spain
| | - Matthis Synofzik
- Hertie-Institute for Clinical Brain Research Tübingen, Tübingen, Germany; German Center for Neurodegenerative Diseases (DZNE) Tübingen, Tübingen, Germany
| | - Caroline Graff
- Karolinska Institutet, Dept NVS, Division of Neurogeriatrics, Stockholm, Sweden; Unit of Hereditary Dementia, Theme Aging, Karolinska University Hospital-Solna, Stockholm, Sweden
| | | | - Maria Carmela Tartaglia
- Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, ON, Canada
| | - James B Rowe
- Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| | - Rik Vandenberghe
- Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium
| | - Elizabeth Finger
- Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada
| | | | | | - Isabel Santana
- Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
| | - Chris Butler
- Department of Clinical Neurology, University of Oxford, Oxford, UK
| | - Simon Ducharme
- Montreal Neurological Institute and McGill University Health Centre, McGill University, Montreal, QC, Canada
| | - Alex Gerhard
- Faculty of Medical and Human Sciences, Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK
| | - Adrian Danek
- Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Munich, Germany
| | - Johannes Levin
- Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Munich, Germany; German Center for Neurodegenerative Diseases, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| | - Markus Otto
- Department of Neurology, Universität Ulm, Ulm, Germany
| | - Giovanni B Frisoni
- IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Stefano Cappa
- IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Yolande A L Pijnenburg
- Alzheimer Center Amsterdam and Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Center, location VU University Medical Center, Amsterdam, Netherlands
| | - Jonathan D Rohrer
- Dementia Research Institute, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - John C van Swieten
- Department of Neurology and Alzheimer Center, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Feis RA, Bouts MJRJ, de Vos F, Schouten TM, Panman JL, Jiskoot LC, Dopper EGP, van der Grond J, van Swieten JC, Rombouts SARB. A multimodal MRI-based classification signature emerges just prior to symptom onset in frontotemporal dementia mutation carriers. J Neurol Neurosurg Psychiatry 2019; 90:1207-1214. [PMID: 31203211 DOI: 10.1136/jnnp-2019-320774] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/08/2019] [Revised: 04/26/2019] [Accepted: 05/12/2019] [Indexed: 12/13/2022]
Abstract
BACKGROUND Multimodal MRI-based classification may aid early frontotemporal dementia (FTD) diagnosis. Recently, presymptomatic FTD mutation carriers, who have a high risk of developing FTD, were separated beyond chance level from controls using MRI-based classification. However, it is currently unknown how these scores from classification models progress as mutation carriers approach symptom onset. In this longitudinal study, we investigated multimodal MRI-based classification scores between presymptomatic FTD mutation carriers and controls. Furthermore, we contrasted carriers that converted during follow-up ('converters') and non-converting carriers ('non-converters'). METHODS We acquired anatomical MRI, diffusion tensor imaging and resting-state functional MRI in 55 presymptomatic FTD mutation carriers and 48 healthy controls at baseline, and at 2, 4, and 6 years of follow-up as available. At each time point, FTD classification scores were calculated using a behavioural variant FTD classification model. Classification scores were tested in a mixed-effects model for mean differences and differences over time. RESULTS Presymptomatic mutation carriers did not have higher classification score increase over time than controls (p=0.15), although carriers had higher FTD classification scores than controls on average (p=0.032). However, converters (n=6) showed a stronger classification score increase over time than non-converters (p<0.001). CONCLUSIONS Our findings imply that presymptomatic FTD mutation carriers may remain similar to controls in terms of MRI-based classification scores until they are close to symptom onset. This proof-of-concept study shows the promise of longitudinal MRI data acquisition in combination with machine learning to contribute to early FTD diagnosis.
Collapse
Affiliation(s)
- Rogier A Feis
- Department of Radiology, Leiden University Medical Centre, Leiden, The Netherlands .,Leiden Institute for Brain and Cognition, Leiden University, Leiden, The Netherlands.,Institute of Psychology, Leiden University, Leiden, The Netherlands
| | - Mark J R J Bouts
- Department of Radiology, Leiden University Medical Centre, Leiden, The Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, Leiden, The Netherlands.,Institute of Psychology, Leiden University, Leiden, The Netherlands
| | - Frank de Vos
- Department of Radiology, Leiden University Medical Centre, Leiden, The Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, Leiden, The Netherlands.,Institute of Psychology, Leiden University, Leiden, The Netherlands
| | - Tijn M Schouten
- Department of Radiology, Leiden University Medical Centre, Leiden, The Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, Leiden, The Netherlands.,Institute of Psychology, Leiden University, Leiden, The Netherlands
| | - Jessica L Panman
- Department of Radiology, Leiden University Medical Centre, Leiden, The Netherlands.,Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands
| | - Lize C Jiskoot
- Department of Radiology, Leiden University Medical Centre, Leiden, The Netherlands.,Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands
| | - Elise G P Dopper
- Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands
| | - Jeroen van der Grond
- Department of Radiology, Leiden University Medical Centre, Leiden, The Netherlands
| | - John C van Swieten
- Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands.,Department of Clinical Genetics, VU University Medical Centre, Amsterdam, The Netherlands
| | - Serge A R B Rombouts
- Department of Radiology, Leiden University Medical Centre, Leiden, The Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, Leiden, The Netherlands.,Institute of Psychology, Leiden University, Leiden, The Netherlands
| |
Collapse
|
13
|
Panman JL, To YY, van der Ende EL, Poos JM, Jiskoot LC, Meeter LHH, Dopper EGP, Bouts MJRJ, van Osch MJP, Rombouts SARB, van Swieten JC, van der Grond J, Papma JM, Hafkemeijer A. Bias Introduced by Multiple Head Coils in MRI Research: An 8 Channel and 32 Channel Coil Comparison. Front Neurosci 2019; 13:729. [PMID: 31379483 PMCID: PMC6648353 DOI: 10.3389/fnins.2019.00729] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2019] [Accepted: 06/28/2019] [Indexed: 12/14/2022] Open
Abstract
Neuroimaging MRI data in scientific research is increasingly pooled, but the reliability of such studies may be hampered by the use of different hardware elements. This might introduce bias, for example when cross-sectional studies pool data acquired with different head coils, or when longitudinal clinical studies change head coils halfway. In the present study, we aimed to estimate this possible bias introduced by using different head coils to create awareness and to avoid misinterpretation of results. We acquired, with both an 8 channel and 32 channel head coil, T1-weighted, diffusion tensor imaging and resting state fMRI images at 3T MRI (Philips Achieva) with stable acquisition parameters in a large group of cognitively healthy participants (n = 77). Standard analysis methods, i.e., voxel-based morphometry, tract-based spatial statistics and resting state functional network analyses, were used in a within-subject design to compare 8 and 32 channel head coil data. Signal-to-noise ratios (SNR) for both head coils showed similar ranges, although the 32 channel SNR profile was more homogeneous. Our data demonstrates specific patterns of gray and white matter volume differences between head coils (relative volume change of 6 to 9%), related to altered image contrast and therefore, altered tissue segmentation. White matter connectivity (fractional anisotropy and diffusivity measures) showed hemispherical dependent differences between head coils (relative connectivity change of 4 to 6%), and functional connectivity in resting state networks was higher using the 32 channel head coil in posterior cortical areas (relative change up to 27.5%). This study shows that, even when acquisition protocols are harmonized, the results of standardized analysis models can be severely affected by the use of different head coils. Researchers should be aware of this when combining multiple neuroimaging MRI datasets, to prevent coil-related bias and avoid misinterpretation of their findings.
Collapse
Affiliation(s)
- Jessica L Panman
- Department of Radiology, Leiden University Medical Center, Leiden, Netherlands.,Department of Neurology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands
| | - Yang Yang To
- Department of Neurology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands
| | - Emma L van der Ende
- Department of Radiology, Leiden University Medical Center, Leiden, Netherlands.,Department of Neurology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands
| | - Jackie M Poos
- Department of Radiology, Leiden University Medical Center, Leiden, Netherlands.,Department of Neurology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands
| | - Lize C Jiskoot
- Department of Radiology, Leiden University Medical Center, Leiden, Netherlands.,Department of Neurology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands
| | - Lieke H H Meeter
- Department of Neurology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands
| | - Elise G P Dopper
- Department of Radiology, Leiden University Medical Center, Leiden, Netherlands.,Department of Neurology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands
| | - Mark J R J Bouts
- Department of Radiology, Leiden University Medical Center, Leiden, Netherlands.,Department of Methodology and Statistics, Institute of Psychology, Leiden University, Leiden, Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, Leiden, Netherlands
| | - Matthias J P van Osch
- Department of Radiology, Leiden University Medical Center, Leiden, Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, Leiden, Netherlands
| | - Serge A R B Rombouts
- Department of Radiology, Leiden University Medical Center, Leiden, Netherlands.,Department of Methodology and Statistics, Institute of Psychology, Leiden University, Leiden, Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, Leiden, Netherlands
| | - John C van Swieten
- Department of Neurology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands
| | | | - Janne M Papma
- Department of Neurology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands
| | - Anne Hafkemeijer
- Department of Radiology, Leiden University Medical Center, Leiden, Netherlands.,Department of Methodology and Statistics, Institute of Psychology, Leiden University, Leiden, Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, Leiden, Netherlands
| |
Collapse
|
14
|
Panman JL, Jiskoot LC, Bouts MJRJ, Meeter LHH, van der Ende EL, Poos JM, Feis RA, Kievit AJA, van Minkelen R, Dopper EGP, Rombouts SARB, van Swieten JC, Papma JM. Gray and white matter changes in presymptomatic genetic frontotemporal dementia: a longitudinal MRI study. Neurobiol Aging 2019; 76:115-124. [PMID: 30711674 DOI: 10.1016/j.neurobiolaging.2018.12.017] [Citation(s) in RCA: 55] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Revised: 12/19/2018] [Accepted: 12/27/2018] [Indexed: 10/27/2022]
Abstract
In genetic frontotemporal dementia, cross-sectional studies have identified profiles of presymptomatic neuroanatomical loss for C9orf72 repeat expansion, MAPT, and GRN mutations. In this study, we characterize longitudinal gray matter (GM) and white matter (WM) brain changes in presymptomatic frontotemporal dementia. We included healthy carriers of C9orf72 repeat expansion (n = 12), MAPT (n = 15), GRN (n = 33) mutations, and related noncarriers (n = 53), that underwent magnetic resonance imaging at baseline and 2-year follow-up. We analyzed cross-sectional baseline, follow-up, and longitudinal GM and WM changes using voxel-based morphometry and cortical thickness analysis in SPM and tract-based spatial statistics in FSL. Compared with noncarriers, C9orf72 repeat expansion carriers showed lower GM volume in the cerebellum and insula, and WM differences in the anterior thalamic radiation, at baseline and follow-up. MAPT mutation carriers showed emerging GM temporal lobe changes and longitudinal WM degeneration of the uncinate fasciculus. GRN mutation carriers did not show presymptomatic neurodegeneration. This study shows distinct presymptomatic cross-sectional and longitudinal patterns of GM and WM changes across C9orf72 repeat expansion, MAPT, and GRN mutation carriers compared with noncarriers.
Collapse
Affiliation(s)
- Jessica L Panman
- Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Lize C Jiskoot
- Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Mark J R J Bouts
- Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands; Institute of Psychology, Leiden University, Leiden, the Netherlands
| | - Lieke H H Meeter
- Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands
| | - Emma L van der Ende
- Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Jackie M Poos
- Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Rogier A Feis
- Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands; Institute of Psychology, Leiden University, Leiden, the Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, the Netherlands
| | - Anneke J A Kievit
- Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands
| | - Rick van Minkelen
- Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands
| | - Elise G P Dopper
- Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands; Department of Neurology, VU medical Center, Amsterdam, the Netherlands
| | - Serge A R B Rombouts
- Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands; Institute of Psychology, Leiden University, Leiden, the Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, the Netherlands
| | - John C van Swieten
- Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Clinical Genetics, VU Medical Center, Amsterdam, the Netherlands
| | - Janne M Papma
- Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands.
| |
Collapse
|
15
|
Feis RA, Bouts MJ, Panman JL, Jiskoot LC, Dopper EG, Schouten TM, de Vos F, van der Grond J, van Swieten JC, Rombouts SA. Corrigendum to ‘Single-subject classification of presymptomatic frontotemporal dementia mutation carriers user multimodal MRI’ NeuroImage: Clinical 20 (2018) 188–196. NeuroImage: Clinical 2019. [DOI: 10.1016/j.nicl.2019.101717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
16
|
Jiskoot LC, Panman JL, Meeter LH, Dopper EGP, Donker Kaat L, Franzen S, van der Ende EL, van Minkelen R, Rombouts SARB, Papma JM, van Swieten JC. Longitudinal multimodal MRI as prognostic and diagnostic biomarker in presymptomatic familial frontotemporal dementia. Brain 2019; 142:193-208. [PMID: 30508042 PMCID: PMC6308313 DOI: 10.1093/brain/awy288] [Citation(s) in RCA: 63] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Revised: 09/26/2018] [Accepted: 10/02/2018] [Indexed: 12/12/2022] Open
Abstract
Developing and validating sensitive biomarkers for the presymptomatic stage of familial frontotemporal dementia is an important step in early diagnosis and for the design of future therapeutic trials. In the longitudinal Frontotemporal Dementia Risk Cohort, presymptomatic mutation carriers and non-carriers from families with familial frontotemporal dementia due to microtubule-associated protein tau (MAPT) and progranulin (GRN) mutations underwent a clinical assessment and multimodal MRI at baseline, 2-, and 4-year follow-up. Of the cohort of 73 participants, eight mutation carriers (three GRN, five MAPT) developed clinical features of frontotemporal dementia ('converters'). Longitudinal whole-brain measures of white matter integrity (fractional anisotropy) and grey matter volume in these converters (n = 8) were compared with healthy mutation carriers ('non-converters'; n = 35) and non-carriers (n = 30) from the same families. We also assessed the prognostic performance of decline within white matter and grey matter regions of interest by means of receiver operating characteristic analyses followed by stepwise logistic regression. Longitudinal whole-brain analyses demonstrated lower fractional anisotropy values in extensive white matter regions (genu corpus callosum, forceps minor, uncinate fasciculus, and superior longitudinal fasciculus) and smaller grey matter volumes (prefrontal, temporal, cingulate, and insular cortex) over time in converters, present from 2 years before symptom onset. White matter integrity loss of the right uncinate fasciculus and genu corpus callosum provided significant classifiers between converters, non-converters, and non-carriers. Converters' within-individual disease trajectories showed a relatively gradual onset of clinical features in MAPT, whereas GRN mutations had more rapid changes around symptom onset. MAPT converters showed more decline in the uncinate fasciculus than GRN converters, and more decline in the genu corpus callosum in GRN than MAPT converters. Our study confirms the presence of spreading predominant frontotemporal pathology towards symptom onset and highlights the value of multimodal MRI as a prognostic biomarker in familial frontotemporal dementia.
Collapse
Affiliation(s)
- Lize C Jiskoot
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
| | - Jessica L Panman
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
| | - Lieke H Meeter
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Elise G P Dopper
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
- Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
| | - Laura Donker Kaat
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
- Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - Sanne Franzen
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
| | | | - Rick van Minkelen
- Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Serge A R B Rombouts
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
- Institute of Psychology, Leiden University, Leiden, The Netherlands
- Leiden Institute for Brain and Cognition, Leiden University, Leiden, The Netherlands
| | - Janne M Papma
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - John C van Swieten
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
| |
Collapse
|
17
|
Jiskoot LC, Bocchetta M, Nicholas JM, Cash DM, Thomas D, Modat M, Ourselin S, Rombouts SA, Dopper EG, Meeter LH, Panman JL, van Minkelen R, van der Ende EL, Donker Kaat L, Pijnenburg YA, Borroni B, Galimberti D, Masellis M, Tartaglia MC, Rowe J, Graff C, Tagliavini F, Frisoni GB, Laforce R, Finger E, de Mendonça A, Sorbi S, Papma JM, van Swieten JC, Rohrer JD. Presymptomatic white matter integrity loss in familial frontotemporal dementia in the GENFI cohort: A cross-sectional diffusion tensor imaging study. Ann Clin Transl Neurol 2018; 5:1025-1036. [PMID: 30250860 PMCID: PMC6144447 DOI: 10.1002/acn3.601] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Accepted: 06/08/2018] [Indexed: 12/12/2022] Open
Abstract
Objective We aimed to investigate mutation-specific white matter (WM) integrity changes in presymptomatic and symptomatic mutation carriers of the C9orf72,MAPT, and GRN mutations by use of diffusion-weighted imaging within the Genetic Frontotemporal dementia Initiative (GENFI) study. Methods One hundred and forty mutation carriers (54 C9orf72, 30 MAPT, 56 GRN), 104 presymptomatic and 36 symptomatic, and 115 noncarriers underwent 3T diffusion tensor imaging. Linear mixed effects models were used to examine the association between diffusion parameters and years from estimated symptom onset in C9orf72,MAPT, and GRN mutation carriers versus noncarriers. Post hoc analyses were performed on presymptomatic mutation carriers only, as well as left-right asymmetry analyses on GRN mutation carriers versus noncarriers. Results Diffusion changes in C9orf72 mutation carriers are present significantly earlier than both MAPT and GRN mutation carriers - characteristically in the posterior thalamic radiation and more posteriorly located tracts (e.g., splenium of the corpus callosum, posterior corona radiata), as early as 30 years before estimated symptom onset. MAPT mutation carriers showed early involvement of the uncinate fasciculus and cingulum, sparing the internal capsule, whereas involvement of the anterior and posterior internal capsule was found in GRN. Restricting analyses to presymptomatic mutation carriers only, similar - albeit less extensive - patterns were found: posteriorly located WM tracts (e.g., posterior thalamic radiation, splenium of the corpus callosum, posterior corona radiata) in presymptomatic C9orf72, the uncinate fasciculus in presymptomatic MAPT, and the internal capsule (anterior and posterior limbs) in presymptomatic GRN mutation carriers. In GRN, most tracts showed significant left-right differences in one or more diffusion parameter, with the most consistent results being found in the UF, EC, RPIC, and ALIC. Interpretation This study demonstrates the presence of early and widespread WM integrity loss in presymptomatic FTD, and suggests a clear genotypic "fingerprint." Our findings corroborate the notion of FTD as a network-based disease, where changes in connectivity are some of the earliest detectable features, and identify diffusion tensor imaging as a potential neuroimaging biomarker for disease-tracking and -staging in presymptomatic to early-stage familial FTD.
Collapse
|
18
|
Feis RA, Bouts MJRJ, Panman JL, Jiskoot LC, Dopper EGP, Schouten TM, de Vos F, van der Grond J, van Swieten JC, Rombouts SARB. Single-subject classification of presymptomatic frontotemporal dementia mutation carriers using multimodal MRI. Neuroimage Clin 2018; 20:188-196. [PMID: 30094168 PMCID: PMC6072645 DOI: 10.1016/j.nicl.2018.07.014] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2018] [Revised: 06/29/2018] [Accepted: 07/15/2018] [Indexed: 11/30/2022]
Abstract
Background Classification models based on magnetic resonance imaging (MRI) may aid early diagnosis of frontotemporal dementia (FTD) but have only been applied in established FTD cases. Detection of FTD patients in earlier disease stages, such as presymptomatic mutation carriers, may further advance early diagnosis and treatment. In this study, we aim to distinguish presymptomatic FTD mutation carriers from controls on an individual level using multimodal MRI-based classification. Methods Anatomical MRI, diffusion tensor imaging (DTI) and resting-state functional MRI data were collected in 55 presymptomatic FTD mutation carriers (8 microtubule-associated protein Tau, 35 progranulin, and 12 chromosome 9 open reading frame 72) and 48 familial controls. We calculated grey and white matter density features from anatomical MRI scans, diffusivity features from DTI, and functional connectivity features from resting-state functional MRI. These features were applied in a recently introduced multimodal behavioural variant FTD (bvFTD) classification model, and were subsequently used to train and test unimodal and multimodal carrier-control models. Classification performance was quantified using area under the receiver operator characteristic curves (AUC). Results The bvFTD model was not able to separate presymptomatic carriers from controls beyond chance level (AUC = 0.570, p = 0.11). In contrast, one unimodal and several multimodal carrier-control models performed significantly better than chance level. The unimodal model included the radial diffusivity feature and had an AUC of 0.646 (p = 0.021). The best multimodal model combined radial diffusivity and white matter density features (AUC = 0.680, p = 0.005). Conclusions FTD mutation carriers can be separated from controls with a modest AUC even before symptom-onset, using a newly created carrier-control classification model, while this was not possible using a recent bvFTD classification model. A multimodal MRI-based classification score may therefore be a useful biomarker to aid earlier FTD diagnosis. The exclusive selection of white matter features in the best performing model suggests that the earliest FTD-related pathological processes occur in white matter.
Collapse
Key Words
- (bv)FTD, (behavioural variant) Frontotemporal dementia
- (rs-f)MRI, (resting-state functional) Magnetic resonance imaging
- 3DT1w, 3-dimensional T1-weighted
- AUC, Area under the receiver operating characteristics curve
- AxD, Axial diffusivity
- C9orf72, Chromosome 9 open reading frame 72
- C9orf72, human
- DTI, Diffusion tensor imaging
- DWI, Diffusion-weighted imaging
- Diffusion Tensor Imaging
- FA, Fractional anisotropy
- FCor, Full correlations
- Frontotemporal dementia
- GM, Grey matter
- GMD, Grey matter density
- GRN protein, human
- GRN, Progranulin
- ICA, Independent component analysis
- MAPT protein, human
- MAPT, Microtubule-associated protein Tau
- MD, Mean diffusivity
- MMSE, Mini-mental state examination
- Multimodal MRI
- Pcor, Sparse L1-regularised partial correlations
- RD, Radial diffusivity
- ROC, Receiver operating characteristics
- Resting-state functional MRI
- TBSS, Tract-based spatial statistics
- WM, White matter
- WMD, White matter density
- classification
- machine learning
Collapse
Affiliation(s)
- Rogier A Feis
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, the Netherlands.
| | - Mark J R J Bouts
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, the Netherlands; Institute of Psychology, Leiden University, Leiden, the Netherlands.
| | - Jessica L Panman
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands; Department of Neurology, Erasmus Medical Centre, Rotterdam, the Netherlands.
| | - Lize C Jiskoot
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands; Department of Neurology, Erasmus Medical Centre, Rotterdam, the Netherlands.
| | - Elise G P Dopper
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands; Department of Neurology, Erasmus Medical Centre, Rotterdam, the Netherlands; Alzheimer Centre & Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, the Netherlands.
| | - Tijn M Schouten
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, the Netherlands; Institute of Psychology, Leiden University, Leiden, the Netherlands.
| | - Frank de Vos
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, the Netherlands; Institute of Psychology, Leiden University, Leiden, the Netherlands.
| | - Jeroen van der Grond
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands.
| | - John C van Swieten
- Department of Neurology, Erasmus Medical Centre, Rotterdam, the Netherlands; Department of Clinical Genetics, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, the Netherlands.
| | - Serge A R B Rombouts
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, the Netherlands; Institute of Psychology, Leiden University, Leiden, the Netherlands.
| |
Collapse
|
19
|
Meeter LHH, Gendron TF, Sias AC, Jiskoot LC, Russo SP, Donker Kaat L, Papma JM, Panman JL, van der Ende EL, Dopper EG, Franzen S, Graff C, Boxer AL, Rosen HJ, Sanchez-Valle R, Galimberti D, Pijnenburg YAL, Benussi L, Ghidoni R, Borroni B, Laforce R, Del Campo M, Teunissen CE, van Minkelen R, Rojas JC, Coppola G, Geschwind DH, Rademakers R, Karydas AM, Öijerstedt L, Scarpini E, Binetti G, Padovani A, Cash DM, Dick KM, Bocchetta M, Miller BL, Rohrer JD, Petrucelli L, van Swieten JC, Lee SE. Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Ann Clin Transl Neurol 2018; 5:583-597. [PMID: 29761121 PMCID: PMC5945959 DOI: 10.1002/acn3.559] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2018] [Accepted: 02/22/2018] [Indexed: 12/12/2022] Open
Abstract
Objective To evaluate poly(GP), a dipeptide repeat protein, and neurofilament light chain (NfL) as biomarkers in presymptomatic C9orf72 repeat expansion carriers and patients with C9orf72‐associated frontotemporal dementia. Additionally, to investigate the relationship of poly(GP) with indicators of neurodegeneration as measured by NfL and grey matter volume. Methods We measured poly(GP) and NfL levels in cerebrospinal fluid (CSF) from 25 presymptomatic C9orf72 expansion carriers, 64 symptomatic expansion carriers with dementia, and 12 noncarriers. We explored associations with grey matter volumes using region of interest and voxel‐wise analyses. Results Poly(GP) was present in C9orf72 expansion carriers and absent in noncarriers (specificity 100%, sensitivity 97%). Presymptomatic carriers had lower poly(GP) levels than symptomatic carriers. NfL levels were higher in symptomatic carriers than in presymptomatic carriers and healthy noncarriers. NfL was highest in patients with concomitant motor neuron disease, and correlated with disease severity and survival. Associations between poly(GP) levels and small grey matter regions emerged but did not survive multiple comparison correction, while higher NfL levels were associated with atrophy in frontotemporoparietal cortices and the thalamus. Interpretation This study of C9orf72 expansion carriers reveals that: (1) poly(GP) levels discriminate presymptomatic and symptomatic expansion carriers from noncarriers, but are not associated with indicators of neurodegeneration; and (2) NfL levels are associated with grey matter atrophy, disease severity, and shorter survival. Together, poly(GP) and NfL show promise as complementary biomarkers for clinical trials for C9orf72‐associated frontotemporal dementia, with poly(GP) as a potential marker for target engagement and NfL as a marker of disease activity and progression.
Collapse
Affiliation(s)
- Lieke H H Meeter
- Alzheimer Center Rotterdam and Department of Neurology Erasmus Medical Center PO Box 2040 3000 CA Rotterdam the Netherlands
| | | | - Ana C Sias
- Department of Neurology Memory and Aging Center University of California San Francisco California
| | - Lize C Jiskoot
- Alzheimer Center Rotterdam and Department of Neurology Erasmus Medical Center PO Box 2040 3000 CA Rotterdam the Netherlands.,Department of Neurodegenerative Diseases Dementia Research Centre Institute of Neurology University College London WC1N 3BG London United Kingdom.,Department of Radiology Leiden University Medical Center Leiden the Netherlands
| | - Silvia P Russo
- Department of Neurology Memory and Aging Center University of California San Francisco California
| | - Laura Donker Kaat
- Alzheimer Center Rotterdam and Department of Neurology Erasmus Medical Center PO Box 2040 3000 CA Rotterdam the Netherlands.,Department of Clinical Genetics Leiden University Medical Center Leiden the Netherlands
| | - Janne M Papma
- Alzheimer Center Rotterdam and Department of Neurology Erasmus Medical Center PO Box 2040 3000 CA Rotterdam the Netherlands
| | - Jessica L Panman
- Alzheimer Center Rotterdam and Department of Neurology Erasmus Medical Center PO Box 2040 3000 CA Rotterdam the Netherlands.,Department of Radiology Leiden University Medical Center Leiden the Netherlands
| | - Emma L van der Ende
- Alzheimer Center Rotterdam and Department of Neurology Erasmus Medical Center PO Box 2040 3000 CA Rotterdam the Netherlands
| | - Elise G Dopper
- Alzheimer Center Rotterdam and Department of Neurology Erasmus Medical Center PO Box 2040 3000 CA Rotterdam the Netherlands
| | - Sanne Franzen
- Alzheimer Center Rotterdam and Department of Neurology Erasmus Medical Center PO Box 2040 3000 CA Rotterdam the Netherlands
| | - Caroline Graff
- Division of Neurogeriatrics Department NVS Karolinska Institutet Center for Alzheimer Research Huddinge 14157 Sweden.,Department of Geriatric Medicine Karolinska Institutet Karolinska University Hospital- Huddinge Stockholm 14186 Sweden
| | - Adam L Boxer
- Department of Neurology Memory and Aging Center University of California San Francisco California
| | - Howard J Rosen
- Department of Neurology Memory and Aging Center University of California San Francisco California
| | - Raquel Sanchez-Valle
- Alzheimer's Disease and Other Cognitive Disorders Unit Department of Neurology Hospital Clínic Institut d'Investigació Biomèdica August Pi i Sunyer Villarroel, 170 Barcelona 08036 Spain
| | - Daniela Galimberti
- University of Milan Fondazione Ca' Granda IRCSS Ospedale Policlinico Milan Italy
| | - Yolande A L Pijnenburg
- Alzheimer Center and Department of Neurology Amsterdam Neuroscience VU University Medical Center PO Box 7057 Amsterdam 1007 MB the Netherlands
| | - Luisa Benussi
- Molecular Markers Laboratory IRCCS Centro San Giovanni di Dio Fatebenefratelli via Pilastroni 4 Brescia 25125 Italy
| | - Roberta Ghidoni
- Molecular Markers Laboratory IRCCS Centro San Giovanni di Dio Fatebenefratelli via Pilastroni 4 Brescia 25125 Italy
| | - Barbara Borroni
- Neurology Unit Department of Clinical and Experimental Sciences Centre for Neurodegenerative Diseases University of Brescia Brescia Italy
| | - Robert Laforce
- Département des Sciences Neurologiques Clinique Interdisciplinaire de Mémoire (CIME) CHU de Québec Université Laval Québec Canada
| | - Marta Del Campo
- Neurochemistry Laboratory Department of Clinical Chemistry Amsterdam Neuroscience VU University Medical Center PO Box 7057 Amsterdam 1007 MB the Netherlands
| | - Charlotte E Teunissen
- Neurochemistry Laboratory Department of Clinical Chemistry Amsterdam Neuroscience VU University Medical Center PO Box 7057 Amsterdam 1007 MB the Netherlands
| | - Rick van Minkelen
- Department of Clinical Genetics Erasmus Medical Center PO Box 2040 Rotterdam 3000 CA the Netherlands
| | - Julio C Rojas
- Department of Neurology Memory and Aging Center University of California San Francisco California
| | - Giovanni Coppola
- Department of Neurology and Department of Psychiatry Semel Institute for Neuroscience and Human Behavior University of California 760 Westwood Plaza Los Angeles California
| | - Dan H Geschwind
- Department of Neurology and Department of Psychiatry Semel Institute for Neuroscience and Human Behavior University of California 760 Westwood Plaza Los Angeles California
| | | | - Anna M Karydas
- Department of Neurology Memory and Aging Center University of California San Francisco California
| | - Linn Öijerstedt
- Division of Neurogeriatrics Department NVS Karolinska Institutet Center for Alzheimer Research Huddinge 14157 Sweden.,Department of Geriatric Medicine Karolinska Institutet Karolinska University Hospital- Huddinge Stockholm 14186 Sweden
| | - Elio Scarpini
- University of Milan Fondazione Ca' Granda IRCSS Ospedale Policlinico Milan Italy
| | - Giuliano Binetti
- Molecular Markers Laboratory IRCCS Centro San Giovanni di Dio Fatebenefratelli via Pilastroni 4 Brescia 25125 Italy.,MAC Memory Center IRCCS Centro San Giovanni di Dio-Fatebenefratelli via Pilastroni 4 Brescia 25125 Italy
| | - Alessandro Padovani
- Neurology Unit Department of Clinical and Experimental Sciences Centre for Neurodegenerative Diseases University of Brescia Brescia Italy
| | - David M Cash
- Department of Neurodegenerative Diseases Dementia Research Centre Institute of Neurology University College London WC1N 3BG London United Kingdom.,Translational Imaging Group Centre for Medical Image Computing University College London London NW1 2HE United Kingdom
| | - Katrina M Dick
- Department of Neurodegenerative Diseases Dementia Research Centre Institute of Neurology University College London WC1N 3BG London United Kingdom
| | - Martina Bocchetta
- Department of Neurodegenerative Diseases Dementia Research Centre Institute of Neurology University College London WC1N 3BG London United Kingdom
| | - Bruce L Miller
- Department of Neurology Memory and Aging Center University of California San Francisco California
| | - Jonathan D Rohrer
- Department of Neurodegenerative Diseases Dementia Research Centre Institute of Neurology University College London WC1N 3BG London United Kingdom
| | | | - John C van Swieten
- Alzheimer Center Rotterdam and Department of Neurology Erasmus Medical Center PO Box 2040 3000 CA Rotterdam the Netherlands.,Department of Clinical Genetics VU University Medical Center PO Box 7057 Amsterdam 1007 MB the Netherlands
| | - Suzee E Lee
- Department of Neurology Memory and Aging Center University of California San Francisco California
| |
Collapse
|
20
|
Papma JM, Jiskoot LC, Panman JL, Dopper EG, den Heijer T, Donker Kaat L, Pijnenburg YA, Meeter LH, van Minkelen R, Rombouts SA, van Swieten JC. Cognition and gray and white matter characteristics of presymptomatic C9orf72 repeat expansion. Neurology 2017; 89:1256-1264. [DOI: 10.1212/wnl.0000000000004393] [Citation(s) in RCA: 68] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2017] [Accepted: 06/29/2017] [Indexed: 11/15/2022] Open
Abstract
Objective:To investigate cognitive function, gray matter volume, and white matter integrity in the presymptomatic stage of chromosome 9 open reading frame 72 repeat expansion (C9orf72RE).Methods:Presymptomatic C9orf72RE carriers (n = 18) and first-degree family members without a pathogenic expansion (healthy controls [HC], n = 15) underwent a standardized protocol of neuropsychological tests, T1-weighted MRI, and diffusion tensor imaging within our cohort study of autosomal dominant frontotemporal dementia (FTD). We investigated group differences in cognitive function, gray matter volume through voxel-based morphometry, and white matter integrity by means of tract-based spatial statistics. We correlated cognitive change with underlying gray or white matter.Results:Our data demonstrate lower scores on letter fluency, Stroop card I, and Stroop card III, accompanied by white matter integrity loss in tracts connecting the frontal lobe, the thalamic radiation, and tracts associated with motor functioning in presymptomatic C9orf72RE compared with HC. In a subgroup of C9orf72RE carriers above 40 years of age, we found gray matter volume loss in the thalamus, cerebellum, and parietal and temporal cortex. We found no significant relationship between subtle cognitive decline and underlying gray or white matter.Conclusions:This study demonstrates that a decline in cognitive functioning, white matter integrity, and gray matter volumes are present in presymptomatic C9orf72RE carriers. These findings suggest that neuropsychological assessment, T1-weighted MRI, and diffusion tensor imaging might be useful to identify early biomarkers in the presymptomatic stage of FTD or amyotrophic lateral sclerosis.
Collapse
|
21
|
Jiskoot LC, Panman JL, Meeter LH, Dopper EG, Heijer T, Minkelen R, Papma JM, Rombouts SA, Swieten JC. [P4–515]: LONGITUDINAL MULTIMODAL NEUROIMAGING IN PRESYMPTOMATIC FRONTOTEMPORAL DEMENTIA: PREDICTING SYMPTOM ONSET IN THE DUTCH FTD RISK COHORT. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.07.677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
| | | | - Lieke H.H. Meeter
- Erasmus MC ‐ University Medical Center RotterdamRotterdamNetherlands
| | | | - Tom Heijer
- VU University Medical CenterAmsterdamNetherlands
| | | | | | | | | |
Collapse
|
22
|
Panman JL, Louise van der Ende E, Meeter LH, Bouts MJ, Dopper EG, Jiskoot LC, Kaat LD, Minkelen R, Teunissen CE, Rombouts SA, Swieten JC, Papma JM. [P2–338]: ARE NEUROFILAMENT LIGHT CHAIN AND WHITE MATTER INTEGRITY RELATED BIOMARKERS FOR FAMILIAL FRONTOTEMPORAL DEMENTIA? Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Jessica L. Panman
- Leiden University Medical CenterLeidenNetherlands
- Erasmus MCRotterdamNetherlands
| | | | | | | | | | - Lize C. Jiskoot
- Leiden University Medical CenterLeidenNetherlands
- Erasmus MCRotterdamNetherlands
| | - Laura Donker Kaat
- Leiden University Medical CenterLeidenNetherlands
- Erasmus MCRotterdamNetherlands
| | | | - Charlotte E. Teunissen
- Department of BiochemistryVU University Medical Center, Amsterdam NeuroscienceAmsterdamNetherlands
| | | | - John C. Swieten
- Erasmus MCRotterdamNetherlands
- VU University Medical CenterAmsterdamNetherlands
| | | |
Collapse
|
23
|
Jiskoot LC, Rombouts SA, Panman JL, Dopper EG, Heijer TD, Franzen S, Pijnenburg YA, Minkelen R, Swieten JC, Papma JM. IC‐P‐079: Neuropsychological and Gray Matter Volume Decline in Presymptomatic C9ORF72 Mutation Carriers. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Lize C. Jiskoot
- Leiden University Medical CenterLeidenNetherlands
- Erasmus Medical CenterRotterdamNetherlands
| | | | | | | | | | | | | | | | - John C. Swieten
- Erasmus Medical CenterRotterdamNetherlands
- Alzheimer Center Neuroscience Campus Amsterdam AmsterdamNetherlands
| | | |
Collapse
|
24
|
Jiskoot LC, Rombouts SA, Panman JL, Dopper EG, Heijer TD, Franzen S, Pijnenburg YA, Minkelen R, Swieten JC, Papma JM. O4‐02‐06: Neuropsychological and Gray Matter Volume Decline in Presymptomatic C9ORF72 Mutation Carriers. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Lize C. Jiskoot
- Erasmus Medical CenterRotterdamNetherlands
- Leiden University Medical CenterLeidenNetherlands
| | | | | | | | | | | | - Yolande A.L. Pijnenburg
- Neuroscience Campus AmsterdamAmsterdamNetherlands
- VU University Medical CenterAmsterdamNetherlands
| | | | | | | |
Collapse
|